Hemophilia A is the textbook example of a sex-linked genetic disease, and the German Shepherd is the textbook breed in which it was documented. If you want to understand why some inherited conditions hammer males while their mothers stay completely healthy, this is the disorder to learn first. It is also a real, preventable problem in shepherd lines — not a historical curiosity.
The short version: hemophilia A is a deficiency of clotting factor VIII, caused by a mutation in the F8 gene, which sits on the X chromosome. Because of where that gene lives, the disease behaves in a way that catches breeders off guard — it appears in male puppies, traces back through apparently normal female lines, and can spread silently for generations.
What Goes Wrong: Factor VIII and the Clotting Cascade
Blood clotting is a relay race. When a vessel is injured, a chain of clotting factors activate one another in sequence until a stable clot forms. Factor VIII is one of the key runners in that relay. Remove it and the cascade stalls — the dog can start a clot but cannot build a stable one, so bleeding continues far longer than it should.
The F8 gene carries the instructions for making factor VIII. A mutation that disables or weakens this gene means little or no functional factor VIII is produced. The severity of the disease tracks closely with how much residual factor VIII activity remains:
- Severe deficiency (very low factor VIII): spontaneous bleeding, bleeding into joints and muscles, dangerous bleeds with no obvious trauma.
- Moderate to mild deficiency: bleeding that looks normal day to day but becomes a crisis after surgery, injury, or a routine procedure like neutering or a dewclaw removal.
This is why some affected dogs are diagnosed as tiny puppies bleeding excessively from the umbilicus or during teething, while others sail through to their first surgery before anyone realises something is wrong.
Why Males Are Hit and Females Hide It
This is the part that makes hemophilia A so instructive. The F8 gene is on the X chromosome, and the mutation is recessive. That single fact drives the entire inheritance pattern.
Males have one X and one Y chromosome (XY). They carry only one copy of the F8 gene. If that single copy is mutated, there is no second copy to compensate — the male is affected. Geneticists call this hemizygous: one bad copy is enough.
Females have two X chromosomes (XX), so they carry two copies of F8. A female with one mutated copy and one normal copy is a carrier. Her healthy copy produces enough factor VIII to clot normally, so she shows no disease. For a female to actually have hemophilia A, she would need two mutated copies — which means an affected father and a carrier or affected mother. That combination is rare, which is why affected females are rare and affected males are not.
The consequence for breeders is the dangerous part. A carrier dam is clinically perfect. She has no symptoms, passes every physical exam, and can be bred for years. Yet she is a silent reservoir for the mutation. This is the same “invisible until you test” problem that shows up across canine genetics, and it is exactly why pedigree-watching alone is never enough — a theme covered in the broader discussion of genetic diversity and inbreeding in white shepherd lines.
How the Mutation Travels Through a Pedigree
Two breeding scenarios cover almost everything you need to predict.
Carrier dam bred to a normal sire. Each son has a 50% chance of inheriting the mutated X — those sons are affected. Each daughter has a 50% chance of being a carrier like her mother. So a single carrier female, bred repeatedly, scatters affected sons and silent carrier daughters across a programme without ever showing a symptom herself.
Affected sire bred to a normal dam. Here is the counter-intuitive case. An affected male — if his disease is mild enough that he survives and breeds — passes his single X to all of his daughters. Every one of them becomes an obligate carrier. His sons, by contrast, receive his Y chromosome and his dam’s normal X, so they are all clear. An affected stud therefore produces zero affected puppies in that litter but converts an entire generation of daughters into carriers. The disease then resurfaces a generation later when those daughters are bred.
This generational skip is precisely why hemophilia A can appear to “come from nowhere.” It did not. It travelled silently through carrier females, exactly the way other heritable conditions move through shepherd lines, including the orthopaedic problems discussed in the analysis of elbow dysplasia genetics in shepherds.
Recognising the Bleeding Phenotype
Affected dogs do not necessarily bleed dramatically all the time. The classic signs to watch for are:
- Prolonged bleeding from minor cuts, the gums during teething, or the umbilicus in neonates
- Large, deep bruises or haematomas after ordinary bumps
- Lameness or swollen, painful joints from bleeding into the joint space (hemarthrosis)
- A bleeding crisis triggered by surgery, dental work, or trauma that should have been routine
Any puppy or young male shepherd that bleeds far more than its littermates after a minor event deserves a coagulation workup before any elective surgery.
Testing and Breeding Decisions
There are two complementary ways to identify the disorder.
Coagulation assays. A factor VIII coagulant activity test measures how much functional factor VIII the dog actually has, and the activated partial thromboplastin time (aPTT) is prolonged in affected dogs. These assays diagnose affected animals reliably. Their weakness is carrier detection: a carrier female’s factor VIII level overlaps with the normal range, so the assay cannot consistently tell a carrier from a clear female.
DNA testing. A genetic test directly identifies the F8 mutation and is the only reliable way to flag carrier females. The important caveat: hemophilia A is caused by many different F8 mutations, often specific to a family or line. A DNA test only finds the variant it is designed to detect. If a line carries a mutation not on the test panel, a “clear” result can be falsely reassuring. When a specific mutation has been identified in a pedigree, the matching DNA test becomes the gold standard for screening relatives.
For a breeding programme, the practical rules are straightforward. Do not breed affected males, however mild — they convert every daughter into a carrier. When the family mutation is known, DNA-test the female line and remove carriers from breeding rather than gambling on which sons inherit the bad X. There is no cure; management of an active bleed relies on plasma or factor-containing transfusions, which is a quality-of-life rescue, not a fix. Prevention through testing is the only real control, and it is well within reach for any breeder willing to screen the dam side as seriously as the sire side.